Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Ross Lifescience Usa Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being processed within a single distinct art unit, showing a concentrated technical focus for the company's current patenting efforts. The company is working with 2 distinct examiners, meaning each pending action is being reviewed by a different person. This arrangement requires the company to adapt its arguments to two different perspectives while remaining within the same technical framework of the art unit.
The busiest examiner, DANDRIDGE, CHRISTOPHER R., is responsible for 1 pending office action. Since the busiest examiner pending count is only half of the total 2 pending actions, the company's prosecution workload is evenly split between the two examiners. This requires the company to manage different examination styles within the Biotechnology & Pharmaceuticals sector. Practitioners must be careful to ensure that responses to one examiner do not create prosecution history estoppel that could negatively impact the other pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DANDRIDGE, CHRISTOPHER R. | 1 | 65.9% | +35.4% |
| AFREMOVA, VERA | 1 | 50.5% | +29.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19066397 | MIST EMITTING DEVICE | DANDRIDGE, CHRISTOPHER R. | — |
| 18767286 | SYNERGISTIC INSECTICIDE COMPOSITIONS AND FORMULATIONS THEREOF | AFREMOVA, VERA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19066397 | MIST EMITTING DEVICE | DANDRIDGE, CHRISTOPHER R. | — |
| 18767286 | SYNERGISTIC INSECTICIDE COMPOSITIONS AND FORMULATIONS THEREOF | AFREMOVA, VERA | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19066397 | MIST EMITTING DEVICE | DANDRIDGE, CHRISTOPHER R. | — | §102§103 | Non-Final OA | — | Pending | Feb 28, 2025 |
| 18767286 | SYNERGISTIC INSECTICIDE COMPOSITIONS AND FORMULATIONS THEREOF | AFREMOVA, VERA | 1653 | §103§112 | Final Rejection | — | Pending | Jul 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial